Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.44 |
| ▸ | NOS3 | P29474 | 6/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721960 | 1.00 | NOS2 (0.44) | NOS2NOS3NOS1BACE1ALDH1A1 | |
| SCHEMBL23147910 | 0.81 | NOS2 (0.39) | NOS2NOS3NOS1BACE1CYP3A4 | |
| SCHEMBL21287270 | 0.81 | NOS3 (0.41) | NOS2NOS3NOS1BACE1ALDH1A1 | |
| SCHEMBL29721971 | 0.81 | NOS2 (0.39) | NOS2NOS3NOS1BACE1CYP3A4 | |
| SCHEMBL32684056 | 0.77 | NOS2 (0.37) | NOS2NOS3NOS1ALDH1A1GAA | |
| SCHEMBL24649102 | 0.77 | NOS3 (0.38) | NOS2NOS3NOS1BACE1ALDH1A1 | |
| SCHEMBL17446861 | 0.76 | NOS2 (0.40) | NOS2NOS3NOS1BACE1PRMT5 | |
| SCHEMBL22289594 | 0.75 | CYP3A4 (0.40) | ALDH1A1GAAMAPTCYP3A4CHRM1 | |
| SCHEMBL21516636 | 0.75 | ALDH1A1 (0.43) | ALDH1A1MAPTCYP3A4CHRM1ALOX15 | |
| SCHEMBL5758060 | 0.75 | NOS2 (0.48) | NOS2NOS3NOS1BACE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4034108-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746090-A | Azaindole carboxamide compounds for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062316-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-3753941-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Blueray Biopharma Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019158019-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | NOS2 1190/4885NOS3 2157/4885NOS1 2470/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | NOS2 4765/4885NOS3 4762/4885NOS1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.